Although current clinical CTLA-4 antibodies do not efficiently deplete Tregs from solid tumors, development of 2nd generation CTLA-4 antibodies for patients that can kill Tregs either systemically or specifically in the tumor microenvironment are nearing the clinic. The gene discussed is CTLA4; the disease is neoplasm.